Jun 4, 2026 – 5.45pmThe exits are flying like confetti at Quadrant Private Equity, where chairman Chris Hadley has placed at least six portfolio companies up for sale in as many weeks.Clinical trials are hot property for PE firms. APSarah Thompson has co-edited Street Talk since 2009, specialising in private equity, investment banking, M&A and equity capital markets stories. Prior to that, she spent 10 years in London as a markets and M&A reporter at Bloomberg and Dow Jones.Kanika Sood is a journalist based in Sydney who writes for the Street Talk column.Emma Rapaport is a co-editor of the Street Talk column. Prior to that, she was a markets reporter at The Australian Financial Review.Subscribe to gift this articleGift 5 articles to anyone you choose each month when you subscribe.Subscribe nowAlready a subscriber?
Quadrant’s exits bonanza set to engulf clinical trials biz Southern Star
It comes as Quadrant has been exploring an IPO for Amart Furniture, while preparing five other portfolio companies for sale processes.
133 words~1 min read
